NASDAQ$ANIK
Anika Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Anika's financial performance increased due to strategic focus and acquisitions, leading to revenue diversification and growth.
Anika Therapeutics reported a 7% year-over-year revenue increase to $31.7 million in Q3 2020. The company repaid $25 million of its outstanding credit facility and continued to expand its joint preservation product portfolio.
- Revenue increased 7% year-over-year to $31.7 million.
- Repaid $25 million of outstanding credit facility.
- Expanded global product portfolio.
- Initiated enrollment in CINGAL Pilot Study and resumed enrollment in HYALOFAST Phase III clinical trial.
Headline financials
Revenue & EPS history
Anika · Revenue · Quarterly
$31.7M
Forward guidance
Anika is positioned to drive sustainable growth and value for all of its stakeholders going forward.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+0.1%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.8%
Avg return
30 days after
51%
33 / 65 earnings
Positive
+32.1%
Q3 2019
Best reaction
-33.0%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.8% | -4.7% | -4.8% | |
| Q4 2025 | +16.8% | +31.6% | +30.5% | |
| Q3 2025 | +0.8% | -0.5% | +2.1% | |
| Q1 2025 | -20.7% | -23.2% | -23.0% | |
| Q4 2024 | -11.1% | -7.3% | -20.3% | |
| Q3 2024 | -33.0% | -34.0% | -28.2% | |
| Q2 2024 | -1.0% | -3.6% | -5.4% | |
| Q1 2024 | -10.9% | -9.9% | -9.1% | |
| Q4 2023 | -4.8% | -2.0% | -3.1% | |
| Q3 2023 | +7.4% | +6.7% | +15.2% | |
| Q2 2023 | -4.9% | -12.7% | -18.0% | |
| Q1 2023 | -2.8% | -3.2% | +3.2% | |
| Q4 2022 | -18.0% | -17.4% | -10.4% | |
| Q3 2022 | +0.3% | +5.3% | +6.3% | |
| Q2 2022 | -4.9% | -2.7% | -6.0% | |
| Q1 2022 | -4.9% | -3.8% | +1.1% | |
| Q4 2021 | -15.9% | -18.0% | -20.1% | |
| Q3 2021 | +3.1% | -8.2% | -12.8% | |
| Q2 2021 | +1.0% | +0.8% | +1.3% | |
| Q1 2021 | +1.3% | +2.8% | +10.9% | |
| Q4 2020 | -10.5% | -12.1% | +3.9% | |
| Q3 2020 | -3.3% | +0.2% | +7.6% | |
| Q2 2020 | +0.3% | -8.7% | +2.9% | |
| Q1 2020 | -9.9% | -12.2% | +9.1% | |
| Q4 2019 | +0.4% | +0.1% | -39.5% | |
| Q3 2019 | +32.1% | +21.5% | +3.7% | |
| Q2 2019 | +29.1% | +31.0% | +37.2% | |
| Q1 2019 | +19.6% | +21.5% | +15.9% | |
| Q4 2018 | -15.3% | -18.8% | -26.5% | |
| Q3 2018 | -11.0% | -13.6% | -13.9% | |
| Q2 2018 | +18.6% | +15.0% | +20.8% | |
| Q1 2018 | -22.9% | -15.7% | -8.6% | |
| Q4 2017 | -4.0% | -11.3% | -17.4% | |
| Q3 2017 | -8.0% | -9.2% | -8.0% | |
| Q2 2017 | +7.1% | +6.0% | +9.3% | |
| Q1 2017 | -5.5% | -1.8% | +0.4% | |
| Q4 2016 | -5.0% | -5.1% | -16.4% | |
| Q3 2016 | +2.0% | +2.7% | +8.0% | |
| Q2 2016 | -5.0% | -2.3% | -6.7% | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +12.5% | — | — | |
| Q2 2015 | +3.2% | — | — | |
| Q1 2015 | -7.5% | — | — | |
| Q4 2014 | -10.7% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2014 | +4.1% | — | — | |
| Q1 2014 | +7.7% | — | — | |
| Q4 2013 | +26.9% | — | — | |
| Q3 2013 | +6.5% | — | — | |
| Q2 2013 | +21.9% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | +16.6% | — | — | |
| Q3 2012 | -7.7% | — | — | |
| Q2 2012 | +24.4% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2009 | +1.5% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q3 2010 | +7.0% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q1 2010 | -1.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro